[{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Gilead Sciences | Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Gilead Sciences | Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Gilead Sciences | Tigermed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Gilead Sciences"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Tenofovir Alafenamide Fumarate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Biktarvy-Generic consists of bictegravir, emtricitabine, and tenofovir alafenamide drugs. This is indicated for the treatment of HIV Infection.

                          Product Name : Biktarvy-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 25, 2025

                          Lead Product(s) : Bictegravir Sodium,Emtricitabine,Tenofovir Alafenamide Fumarate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Nanfang Hospital, Southern Medical University

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Nanfang Hospital, Southern Medical University

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Tenofovir Alafenamide Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 05, 2022

                          Lead Product(s) : Tenofovir Alafenamide Fumarate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Gilead Sciences | Tigermed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Tenofovir Alafenamide Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 10, 2021

                          Lead Product(s) : Tenofovir Alafenamide Fumarate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Gilead Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank